Ascend Gene & Cell Therapies

• 10/05/2023
• Series A
• $132,500,000

At Ascend we aim high.

Ascend was founded to address the need for quality manufacturing capacity for any gene and cell therapy developer. We offer starting material, process and formulation development, clinical manufacturing, analytical and regulatory support to biotech companies working in advanced modalities who need flexible chemistry, manufacturing and controls (CMC) services.

Our team of approximately 120 cross-functional experts in the UK, Germany and United States are on a mission to create the most effective, highest-quality, scalable gene therapies possible.

Operating an efficient, streamlined model, we provide more than just a service. We’re a team of highly skilled, experienced individuals with a hunger to help you succeed – whether that’s by innovating new techniques and solving unexpected problems, or by offering honest advice.

With origins in biopharma, our expert teams have “been there and done that” with regulators. They understand the quality and potency of your product is just as important as the yield. Beyond that, the Ascend specialists have the next-generation platforms and capabilities you need to ensure clinical and commercial success.

The result? Consistently high quality and low risk for you. Put simply, we offer the service you need for you to Aim Higher.

---

---